News
The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...
Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk has agreed a partnership worth up to $2.2bn with US biotech Septerna, as the Danish drugmaker tries to shore up its pipeline of potential next-generation obesity drugs. The pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback